Scholars Central

Conference abstract

Stability indicating RP-HPLC method development and validation for the simultaneous estimation of darunavir and cobicistat in pharmaceutical dosage form

Authors: Sridhar Siddiraju

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Darunavir is a protease inhibitor medication used to treat HIV infection. Cobicistat is a pharmacokinetic enhancer used along with anti HIV agents. The US Food and Drug Administration has approved a fixed-dose combination of Darunavir (800 mg) and Cobicistat (150 mg) for HIV treatment in 2015. In the present work, we planned to develop a simple, fast, accurate and precise RPHPLC method for the simultaneous estimation of Darunavir and Cobicistat in pharmaceutical dosage form. The chromatographic method was developed by using Kromosil C18 column (250mm x 4.6mm, 5μm) and the mobile phase was pumped with acetonitrile and water (pH was adjusted to 3.2 by using ortho phosphoric acid) in the ratio of 70:30 v/v. The mobile phase was pumped at 1ml/min flow rate and the temperature was maintained at 30oC. The retention times of Darunavir and Cobicistat were found to be 3.5 min and 2.7 min, respectively. The method developed was validated in accordance with ICH guidelines with respect to the stability indicating capacity of the method including system suitability, accuracy, precision, linearity, range, limit of detection, limit of quantification, solution stability and robustness. Darunavir and Cobicistat were found to be linear in the range of 40-240 μg/ml and 7.5-45 μg/ml, respectively. The assay results of Darunavir and Cobicistat in PREZCOBIX were found to be 100.4% and 100.9%, respectively. The sample solution was tested for degradation studies in acidic, basic, neutral, peroxide, heat, photolytic conditions and the percentage degradation was found to be within the limits. The developed methods can be used for the routine analysis of the drugs in pharmaceutical dosage forms.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Pharmaceutica Analytica Acta.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutica Analytica Acta
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Sridhar Siddiraju”